GSK production coming up short for meningitis B vax, causing some shortages

GlaxoSmithKline ($GSK) says "unexpected global demand" for its meningitis B vaccine Bexsero has resulted in "supply constraints," which in turn has led to a shortage for private clinics in the U.K. The U.K.-based drugmaker told FierceVaccines that it hopes to have the situation resolved by summer. The drugmaker says the shortage is not affecting its agreement with the U.K. National Health Service, struck last year, to create the world's first national meningitis B vaccination program. GSK got the vaccine in its asset swap with Novartis ($NVS). The FDA approved the jab a year ago. The U.K. vax program began in the fall with the vaccine being offered to British infants at two months, four months and 12 to 13 months. More from FierceVaccines

Suggested Articles

The FDA asked five drugmakers to pull their version of extended-release metformin off U.S. shelves after finding carcinogen contamination.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.

GSK has formed several collaborations across the globe that will use its AS03 adjuvant to develop vaccines against the novel coronavirus.